Liquid Biopsy, CtDNA Diagnosis Through NGS

Overview

Journal Life (Basel)

Specialty Biology

Date 2021 Sep 28

PMID 34575039

Citations 41

Authors

Chen Lin

Xuzhu Liu

Bingyi Zheng

Rongqin Ke

Chi-Meng Tzeng

Affiliations

Soon will be listed here.

Abstract

Liquid biopsy with circulating tumor DNA (ctDNA) profiling by next-generation sequencing holds great promise to revolutionize clinical oncology. It relies on the basis that ctDNA represents the real-time status of the tumor genome which contains information of genetic alterations. Compared to tissue biopsy, liquid biopsy possesses great advantages such as a less demanding procedure, minimal invasion, ease of frequent sampling, and less sampling bias. Next-generation sequencing (NGS) methods have come to a point that both the cost and performance are suitable for clinical diagnosis. Thus, profiling ctDNA by NGS technologies is becoming more and more popular since it can be applied in the whole process of cancer diagnosis and management. Further developments of liquid biopsy ctDNA testing will be beneficial for cancer patients, paving the way for precision medicine. In conclusion, profiling ctDNA with NGS for cancer diagnosis is both biologically sound and technically convenient.

Citing Articles

Liquid biopsy in gastric cancer: A snapshot of the current state of the art.

Gasparello J, Ceccon C, Angerilli V, Comunello T, Sabbadin M, DAlmeida Costa F J Liq Biopsy. 2025; 7:100288.

PMID: 40027230 PMC: 11863821. DOI: 10.1016/j.jlb.2025.100288.

The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS Era.

Costa J, Membrino A, Zanchetta C, Rizzato S, Cortiula F, Rossetto C Int J Mol Sci. 2025; 25(24.

PMID: 39769431 PMC: 11727717. DOI: 10.3390/ijms252413669.

Rectal Cancer: Exploring Predictive Biomarkers Through Molecular Pathways Involved in Carcinogenesis.

Martins S, Veiga P, Tralhao J, Carreira I, Ribeiro I Biology (Basel). 2025; 13(12.

PMID: 39765674 PMC: 11673418. DOI: 10.3390/biology13121007.

The role of circulating tumor DNA in melanomas of the uveal tract.

Zameer M, Jou E, Middleton M Front Immunol. 2024; 15():1509968.

PMID: 39697328 PMC: 11652350. DOI: 10.3389/fimmu.2024.1509968.

Liquid biopsy in cancer current: status, challenges and future prospects.

Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J Signal Transduct Target Ther. 2024; 9(1):336.

PMID: 39617822 PMC: 11609310. DOI: 10.1038/s41392-024-02021-w.

References

Veatch J, Jesernig B, Kargl J, Fitzgibbon M, Lee S, Baik C . Endogenous CD4 T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic and () Driver Mutations. Cancer Immunol Res. 2019; 7(6):910-922. PMC: 6584616. DOI: 10.1158/2326-6066.CIR-18-0402. View

Bai Y, Wang Z, Liu Z, Liang G, Gu W, Ge Q . Technical progress in circulating tumor DNA analysis using next generation sequencing. Mol Cell Probes. 2019; 49:101480. DOI: 10.1016/j.mcp.2019.101480. View

Yang Y, Huang J, Wang T, Zhou J, Zheng J, Feng J . Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing. J Thorac Oncol. 2021; 16(5):827-839. DOI: 10.1016/j.jtho.2021.01.1615. View

Zhao L, Wu X, Li T, Luo J, Dong D . ctcRbase: the gene expression database of circulating tumor cells and microemboli. Database (Oxford). 2020; 2020. PMC: 7158883. DOI: 10.1093/database/baaa020. View

Liang N, Li B, Jia Z, Wang C, Wu P, Zheng T . Ultrasensitive detection of circulating tumour DNA via deep methylation sequencing aided by machine learning. Nat Biomed Eng. 2021; 5(6):586-599. DOI: 10.1038/s41551-021-00746-5. View

Annala M, Taavitsainen S, Khalaf D, Vandekerkhove G, Beja K, Sipola J . Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. Clin Cancer Res. 2021; 27(16):4610-4623. DOI: 10.1158/1078-0432.CCR-21-1625. View

Tachtsidis A, McInnes L, Jacobsen N, Thompson E, Saunders C . Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells. Clin Exp Metastasis. 2016; 33(6):521-50. PMC: 4947105. DOI: 10.1007/s10585-016-9796-8. View

Killock D . Diagnosis: CancerSEEK and destroy - a blood test for early cancer detection. Nat Rev Clin Oncol. 2018; 15(3):133. DOI: 10.1038/nrclinonc.2018.21. View

Patel K, Tsui D . The translational potential of circulating tumour DNA in oncology. Clin Biochem. 2015; 48(15):957-61. DOI: 10.1016/j.clinbiochem.2015.04.005. View

10.

Fritsch E, Burkhardt U, Hacohen N, Wu C . Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved. Cancer Immunol Res. 2020; 8(12):1465-1469. PMC: 7717540. DOI: 10.1158/2326-6066.CIR-20-0526. View

11.

Fiala C, Diamandis E . Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. BMC Med. 2018; 16(1):166. PMC: 6167864. DOI: 10.1186/s12916-018-1157-9. View

12.

Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S . Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005; 102(45):16368-73. PMC: 1283450. DOI: 10.1073/pnas.0507904102. View

13.

Zhang Z, Lu M, Qin Y, Gao W, Tao L, Su W . Neoantigen: A New Breakthrough in Tumor Immunotherapy. Front Immunol. 2021; 12:672356. PMC: 8085349. DOI: 10.3389/fimmu.2021.672356. View

14.

Su C, Jiang Y, Jiang W, Wang H, Liu S, Shao Y . Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review. Onco Targets Ther. 2020; 13:12515-12519. PMC: 7727031. DOI: 10.2147/OTT.S282933. View

15.

Gale D, Lawson A, Howarth K, Madi M, Durham B, Smalley S . Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA. PLoS One. 2018; 13(3):e0194630. PMC: 5856404. DOI: 10.1371/journal.pone.0194630. View

16.

Martignano F, Munagala U, Crucitta S, Mingrino A, Semeraro R, Del Re M . Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients. Mol Cancer. 2021; 20(1):32. PMC: 7881593. DOI: 10.1186/s12943-021-01327-5. View

17.

Sueoka-Aragane N, Nakashima C, Yoshida H, Matsumoto N, Iwanaga K, Ebi N . The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment. Cancer Med. 2021; 10(12):3873-3885. PMC: 8209625. DOI: 10.1002/cam4.3929. View

18.

Malone E, Oliva M, Sabatini P, Stockley T, Siu L . Molecular profiling for precision cancer therapies. Genome Med. 2020; 12(1):8. PMC: 6961404. DOI: 10.1186/s13073-019-0703-1. View

19.

Schwarzenbach H, Hoon D, Pantel K . Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11(6):426-37. DOI: 10.1038/nrc3066. View

20.

Cohen J, Javed A, Thoburn C, Wong F, Tie J, Gibbs P . Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci U S A. 2017; 114(38):10202-10207. PMC: 5617273. DOI: 10.1073/pnas.1704961114. View